Spyre Therapeutics, Inc.
SYRE· Nasdaq
SYRESpyre Therapeutics, Inc.
Filed Mar 13, 2018 · 10-K · 72 days after period end · 0001564590-18-005404
| Metric | Q4 2017 | Q4 2016 | Q4 2015 |
|---|---|---|---|
| Revenue | $1.48M | — | — |
| Net Income | -$6.48M | -$5.48M | -$3.99M |
| EPS Diluted | -$0.39 | -$0.41 | -$6.36 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spyre Therapeutics, Inc. · CIK 1636282 · Engraved from SEC EDGAR
ended Dec 31, 2017 · filed Mar 13, 2018 · 72 d after period end
